CR11020A - Compuestos amino-5-[-4-(difluorometoxi)fenil suatituido]-5-fenilimidazolona como inhibidores de b-secretasa - Google Patents

Compuestos amino-5-[-4-(difluorometoxi)fenil suatituido]-5-fenilimidazolona como inhibidores de b-secretasa

Info

Publication number
CR11020A
CR11020A CR11020A CR11020A CR11020A CR 11020 A CR11020 A CR 11020A CR 11020 A CR11020 A CR 11020A CR 11020 A CR11020 A CR 11020A CR 11020 A CR11020 A CR 11020A
Authority
CR
Costa Rica
Prior art keywords
amino
phenylimidazolone
substituted phenyl
difluorometoxi
compounds
Prior art date
Application number
CR11020A
Other languages
English (en)
Inventor
Michael Sotirios Malamas
Albert Jean Robichaud
Alexander Michael Porte
William Ronald Solvibile
Koi Michele Morris
Schuyler Adam Antane
Ji-In Kim
Robert Emmett Mcdevitt
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR11020A publication Critical patent/CR11020A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion proporciona un compuesto 2-amino-5-[-4-(difluorometoxi)fenil sustituido]-5-fenilimidazolona de la formula l. Tambien proporciona metodos para uso de estos para inhibir b-secretasa (BACE) y tratar depositos b- amiloides y ovillos neurofibrilares.
CR11020A 2007-03-20 2009-09-09 Compuestos amino-5-[-4-(difluorometoxi)fenil suatituido]-5-fenilimidazolona como inhibidores de b-secretasa CR11020A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91908707P 2007-03-20 2007-03-20

Publications (1)

Publication Number Publication Date
CR11020A true CR11020A (es) 2009-10-06

Family

ID=39564223

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11020A CR11020A (es) 2007-03-20 2009-09-09 Compuestos amino-5-[-4-(difluorometoxi)fenil suatituido]-5-fenilimidazolona como inhibidores de b-secretasa

Country Status (24)

Country Link
US (1) US20090042964A1 (es)
EP (1) EP2137161A1 (es)
JP (1) JP2010522235A (es)
KR (1) KR20100015376A (es)
CN (1) CN101641335A (es)
AR (1) AR065811A1 (es)
AU (1) AU2008229327A1 (es)
BR (1) BRPI0808944A2 (es)
CA (1) CA2681243A1 (es)
CL (1) CL2008000784A1 (es)
CO (1) CO6140056A2 (es)
CR (1) CR11020A (es)
EC (1) ECSP099639A (es)
GT (1) GT200900241A (es)
IL (1) IL200961A0 (es)
MX (1) MX2009009699A (es)
NI (1) NI200900164A (es)
PA (1) PA8772701A1 (es)
PE (1) PE20090160A1 (es)
RU (1) RU2009133807A (es)
SV (1) SV2009003373A (es)
TW (1) TW200845965A (es)
WO (1) WO2008115552A1 (es)
ZA (1) ZA200906542B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
PE20070135A1 (es) 2005-06-14 2007-03-09 Schering Corp Compuestos heterociclicos como inhibidores de aspartil proteasas
WO2010021680A2 (en) 2008-08-19 2010-02-25 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
EP2184276A1 (en) * 2008-11-07 2010-05-12 Universite Paul Cezanne Aix-Marseille Iii Process to prepare new substituted 1H-Benzo(d) imidazol-2(3h)-Ones, New intermediates and their use as bace 1 inhibitors
MX2011009571A (es) 2009-03-13 2011-10-19 Boehringer Ingelheim Int Inhibidores de beta-secretasa.
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
JP5828848B2 (ja) 2010-02-24 2015-12-09 ヴァイティー ファーマシューティカルズ，インコーポレイテッド ベータセクレターゼインヒビター
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
CN103874496A (zh) 2011-08-22 2014-06-18 默沙东公司 作为bace抑制剂的2-螺-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其用途
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
TW201422592A (zh) 2012-08-27 2014-06-16 Boehringer Ingelheim Int β－分泌酶抑制劑
JP2015532282A (ja) 2012-09-28 2015-11-09 ヴァイティー ファーマシューティカルズ，インコーポレイテッド β−セクレターゼの阻害剤
CA2899938C (en) * 2013-02-12 2021-10-19 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
US20160298151A1 (en) 2015-04-09 2016-10-13 Sher Ali Butt Novel Method for the cheap, efficient, and effective production of pharmaceutical and therapeutic api's intermediates, and final products
EP3784242A4 (en) * 2018-04-23 2021-12-22 Merck Sharp & Dohme Corp. NEW PROCESS FOR PREPARING A PHENOXYDIAMINOPYRIMIDINE COMPOUND
CN109289696B (zh) * 2018-10-29 2022-03-22 天津先光化工有限公司 一种咪唑啉两性表面活性剂的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE45198B1 (en) * 1976-06-05 1982-07-14 Wyeth John & Brother Ltd Guanidine derivatives
GB1588096A (en) * 1978-05-20 1981-04-15 Wyeth & Bros Ltd John Pyrrole derivatives
GB9511694D0 (en) * 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US6492408B1 (en) * 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
DE10046993A1 (de) * 2000-09-22 2002-04-11 Aventis Pharma Gmbh Substituierte Zimtsäureguanidide, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltendes Medikament
AU2003229024A1 (en) * 2002-05-07 2003-11-11 Elan Pharmaceuticals, Inc. Succinoyl aminopyrazoles and related compounds
US7700603B2 (en) * 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
BRPI0512213A (pt) * 2004-06-16 2008-02-19 Wyeth Corp método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
RU2006144075A (ru) * 2004-06-16 2008-07-27 Вайет (Us) ДИФЕНИЛИМИДАЗОПИРИМИДИН И -ИМИДАЗОЛАМИНЫ КАК ИНГИБИТОРЫ β-СЕКРЕТАЗЫ
CA2593515A1 (en) * 2005-01-14 2006-07-20 Wyeth Amino-imidazolones for the inhibition of beta-secretase
CN101111489A (zh) * 2005-02-01 2008-01-23 惠氏公司 作为β-分泌酶的抑制剂的氨基-吡啶
BRPI0606902A2 (pt) * 2005-02-14 2009-07-28 Wyeth Corp composto; método para o tratamento de uma doença ou distúrbio associado a atividade excessiva de bace em um paciente que dele necessite; método para modular a atividade de bace; composição farmacêutica
WO2006088694A1 (en) * 2005-02-14 2006-08-24 Wyeth SUBSTITUTED THIENYL AND FURYL ACYLGUANIDINES AS β-SECRETASE MODULATORS
WO2006088705A1 (en) * 2005-02-14 2006-08-24 Wyeth Terphenyl guanidines as [beta symbol] -secretase inhibitors
AU2006266167A1 (en) * 2005-06-30 2007-01-11 Wyeth Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation
TW200738683A (en) * 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
TW200730523A (en) * 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
JP2009509957A (ja) * 2005-09-26 2009-03-12 ワイス β−セクレターゼ阻害剤としてのアミノ−５−［４−（ジフルオロメトキシ）フェニル］−５−フェニルイミダゾロン化合物
AU2006333049A1 (en) * 2005-12-19 2007-07-12 Wyeth 2-amino-5-piperidinylimidazolone compounds and use thereof for beta-secretase modulation
WO2007100536A1 (en) * 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
US7700606B2 (en) * 2006-08-17 2010-04-20 Wyeth Llc Imidazole amines as inhibitors of β-secretase
WO2008036196A2 (en) * 2006-09-21 2008-03-27 Wyeth Indolylalkylpyridin-2-amines for the inhibition of beta-secretase

Also Published As

Publication number Publication date
IL200961A0 (en) 2010-05-17
RU2009133807A (ru) 2011-04-27
EP2137161A1 (en) 2009-12-30
MX2009009699A (es) 2009-09-24
BRPI0808944A2 (pt) 2014-09-02
AR065811A1 (es) 2009-07-01
NI200900164A (es) 2010-07-29
KR20100015376A (ko) 2010-02-12
ZA200906542B (en) 2010-06-30
TW200845965A (en) 2008-12-01
PE20090160A1 (es) 2009-02-11
CL2008000784A1 (es) 2008-05-30
JP2010522235A (ja) 2010-07-01
ECSP099639A (es) 2009-10-30
CA2681243A1 (en) 2008-09-25
US20090042964A1 (en) 2009-02-12
CN101641335A (zh) 2010-02-03
AU2008229327A8 (en) 2009-10-15
WO2008115552A1 (en) 2008-09-25
CO6140056A2 (es) 2010-03-19
GT200900241A (es) 2010-05-07
PA8772701A1 (es) 2008-11-19
SV2009003373A (es) 2010-08-10
AU2008229327A1 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
CR11020A (es) Compuestos amino-5-[-4-(difluorometoxi)fenil suatituido]-5-fenilimidazolona como inhibidores de b-secretasa
CR9244A (es) AMINO-IMIDAZOLONAS PARA LA INHIBICION DE ß-SECRETASA
CR9830A (es) Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la b-secretasa
EA201270149A1 (ru) Ингибиторы bace
CR11776A (es) Inhibidores de bace
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
CR9331A (es) Inhibidores de vegf-r2 y metodos
UA110338C2 (xx) Хімічні сполуки
UA107796C2 (en) Tetracyclic compound
DK1761520T3 (da) Kinaseinhibitorer
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
UY29612A1 (es) Compuestos quimicos ii
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
MX2010002902A (es) Pirimidinas anti-infecciosas y usos de las mismas.
MA32551B1 (fr) Nouveaux composes utiles pour le traitement de maladies degeneratives et inflammatoires
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
EA200900945A1 (ru) Новый способ синтеза агомелатина
UY32384A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
SG171593A1 (en) Inhibitors of c-fms kinase
EA201200891A1 (ru) Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина
CR20120502A (es) Uso de nuevos inhibidores de pan-cdk para tratar tumores
BRPI0921868A2 (pt) inibidores de fosfodiesterase tipo iii (pde iii) ou agentes de sensibilizacao de ca2+ para o tratamento de cardiomiopatia hipertrofica
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
EA200900944A1 (ru) Новый способ получения кристаллической формы v агомелатина
ATE551061T1 (de) Lna-nukleosid-phosphoramidate